Av. da Saudade, 2147 - Parque Res. Friozi, Votuporanga - SP, 15501-405, Brasil
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Wagner Telini
Bethina Sanches
Gracielly Pantano
Kamila Maria Negri
Guilherme Fazolli
Mauro Esteves Hernandes
Fabio Prates
Gabriela Pantano
Ana Barao
Open studies
Cardiovascular disease
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) - MOVE-Lp(a) - Eli Lilly and CompanySee more
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
Elevated Lipoprotein A
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) - MOVE-Lp(a) - Eli Lilly and CompanySee more
Crohn's disease
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease - AMAY - Eli Lilly and CompanySee more
Chronic obstructive pulmonary disease
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) - EMBARK - AstraZenecaSee more
Obesity
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity - MARITIME-CV - AmgenSee more
Renal disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more